STRATA Skin Sciences (SSKN) Trading 6.7% Higher

Shares of STRATA Skin Sciences Inc (NASDAQ:SSKN) traded up 6.7% during trading on Friday . The stock traded as high as $1.62 and last traded at $1.74. 15,156 shares traded hands during mid-day trading, a decline of 82% from the average session volume of 85,148 shares. The stock had previously closed at $1.63.

Several analysts recently commented on the company. ValuEngine raised STRATA Skin Sciences from a “sell” rating to a “hold” rating in a report on Thursday, March 1st. Zacks Investment Research raised STRATA Skin Sciences from a “sell” rating to a “hold” rating in a report on Thursday, January 11th.

The company has a debt-to-equity ratio of 0.35, a current ratio of 1.40 and a quick ratio of 1.01. The firm has a market capitalization of $7.10 million, a P/E ratio of 0.81 and a beta of 0.65.

STRATA Skin Sciences (NASDAQ:SSKN) last issued its quarterly earnings data on Monday, April 2nd. The medical device company reported ($0.10) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.27) by $1.17. STRATA Skin Sciences had a negative return on equity of 39.24% and a negative net margin of 58.76%. The company had revenue of $8.60 million during the quarter, compared to analyst estimates of $7.35 million. equities analysts predict that STRATA Skin Sciences Inc will post -1.05 earnings per share for the current fiscal year.

Several institutional investors and hedge funds have recently modified their holdings of the stock. Sabby Management LLC grew its holdings in shares of STRATA Skin Sciences by 58.3% in the fourth quarter. Sabby Management LLC now owns 335,105 shares of the medical device company’s stock worth $416,000 after acquiring an additional 123,410 shares during the period. Renaissance Technologies LLC grew its holdings in shares of STRATA Skin Sciences by 80.0% in the fourth quarter. Renaissance Technologies LLC now owns 95,620 shares of the medical device company’s stock worth $118,000 after acquiring an additional 42,500 shares during the period. Finally, Broadfin Capital LLC grew its holdings in shares of STRATA Skin Sciences by 325.2% in the fourth quarter. Broadfin Capital LLC now owns 203,346 shares of the medical device company’s stock worth $250,000 after acquiring an additional 155,521 shares during the period. 18.89% of the stock is owned by institutional investors.

STRATA Skin Sciences Company Profile

STRATA Skin Sciences, Inc, a medical technology company, engages in developing and commercializing products for the treatment of dermatological disorders. Its products include XTRAC and VTRAC devices used for the treatment of psoriasis, vitiligo, and other skin disorders; and MelaFind system, an instrument for aiding dermatologists in the evaluation of clinically atypical pigmented skin lesions, when a dermatologist chooses to obtain additional information before making a final decision to biopsy in order to rule out melanoma.

Receive News & Ratings for STRATA Skin Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STRATA Skin Sciences and related companies with MarketBeat.com's FREE daily email newsletter.




Leave a Reply